PDGF Storage, Stability and Handling: What the Literature Covers

What "storage" and "stability" mean in the PDGF literature

PDGF (platelet-derived growth factor) describes a family of dimeric growth factors — including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD — that signal through the PDGFRα and PDGFRβ receptors. Anyone reading the PDGF literature for handling or shelf-life information runs into a vocabulary problem immediately: the words "storage," "stability" and "degradation" all carry biological meanings in this field that have nothing to do with a vial in a refrigerator.

A clear example is the 2021 Science paper in which researchers reported that diet-regulated production of PDGFcc by macrophages controlled energy storage (PMID 34210853) — "storage" there refers to adipose tissue energy handling in an animal model, not to product handling. Similarly, the 2018 Cell paper describing circuit design features of a stable two-cell system used "stable" to describe the dynamics of a cell-cell signaling circuit (PMID 29398113), not the physical stability of a protein preparation. This page keeps those meanings separate from physical and chemical stability of the molecule itself.

Compound-specific evidence versus general lyophilized-protein science

Stated plainly: within the verified citation set for this page there is no PDGF-specific stability study — no published real-time or accelerated degradation kinetics for recombinant PDGF, no freeze-thaw cycling assay, no reconstituted-solution hold-time data. Any statement on this page about refrigeration, freezing or shelf life that is not tied to a PubMed link is a general protein-formulation principle, described here as background, and is not a measured PDGF result.

The closest compound-adjacent evidence falls into three groups, and the table below indicates which claims rest on cited studies and which rest on general formulation science.

Refrigeration: lyophilized powder versus reconstituted solution

The general principle in protein formulation — not a PDGF measurement — is that residual water and molecular mobility drive most chemical decay pathways. In a properly dried lyophilized cake, water activity is low and the protein is kinetically trapped, so hydrolysis, deamidation and aggregation proceed far more slowly than in solution. Once a protein is in aqueous buffer, it becomes exposed to hydrolytic and oxidative chemistry, surface adsorption at glass and plastic interfaces, air-liquid interface stress, and any proteolytic contamination present. That is why reconstituted growth-factor solutions are generally treated as short-lived relative to the dry format, and why suppliers of research-grade proteins describe cold storage for powders and shorter cold windows for solutions.

The verified literature does not quantify any of this for PDGF. What it does show is that lyophilization is used deliberately as a stabilizing format for growth-factor-containing biologics: in an experimental and comparative study of lyophilized autologous serum eyedrops, researchers prepared a lyophilized version of a serum-derived preparation and compared it against conventional formats (PMID 32006480). That study concerns a serum eyedrop product rather than purified recombinant PDGF, so it is context for why dry formats exist — not a PDGF stability result.

Regulatory context. Recombinant human PDGF-BB reached the market in the United States as becaplermin, a formulated topical gel, and its manufacturer labeling specifies refrigerated storage in the 2–8 °C range and states that the product should not be frozen. That is labeling information for a finished, buffered gel — a different physical system from a lyophilized research powder or a laboratory-prepared solution — and it is cited here as a regulatory fact rather than as an experimental finding.

Shelf life and expiry dating: what is and is not published

Manufacturer shelf-life statements for protein products are generated by formal stability programmes: real-time storage at the labeled condition, accelerated conditions at elevated temperature and humidity, and stress testing, with potency measured by a defined bioassay at each timepoint. Those datasets sit in regulatory filings and certificates of analysis rather than in the peer-reviewed PDGF literature, which is why a search of published PDGF papers returns no expiry curve for the molecule.

Two consequences follow for readers interpreting shelf-life claims. First, an expiry date on research-grade material is a supplier assertion tied to a specified storage condition, and it does not transfer to material held under different conditions. Second, published PDGF experiments almost never report how long their protein had been stored, so the literature cannot be mined retrospectively for a shelf-life estimate. Where studies did characterise longevity, they characterised it in a carrier system rather than in a vial: the supramolecular hydrogel study built the delivery vehicle from PDGF-BB itself and reported that the hydrogel promoted skin wound healing (PMID 35473604).

Room temperature and transit

General formulation science holds that lyophilized proteins tolerate ambient shipping far better than solutions, which is why dry biologics are frequently transported without a full cold chain and refrigerated on arrival, while aqueous formulations travel with cold packs. Temperature excursions matter less for a dry cake because the dominant degradation routes require molecular mobility; they matter more for solutions, where aggregation and hydrolysis rates rise with temperature. None of that is PDGF-measured in the verified set.

What the PDGF literature does demonstrate is that the protein retained biological activity in warm, wet, in-use environments once formulated appropriately. Researchers reported that factor-decorated fibrin matrices drove therapeutic arteriogenesis and promoted wound healing in diabetic mice (PMID 36093431), and a 2024 Science Advances study reported that biologically inspired bioactive hydrogels supported scarless corneal repair (PMID 39693435). Those are in-use performance results at body temperature inside an engineered matrix, not evidence about how long an unformulated preparation survives on a bench or in a courier bag.

Freezing and freeze–thaw

The general risks described for frozen protein solutions are well rehearsed in formulation literature and are repeated here as background, not as PDGF findings: ice formation concentrates solutes and can shift buffer pH, the expanding ice–water interface unfolds protein at the surface, and each additional freeze–thaw cycle adds another exposure to that interface, which is why aliquoting is the standard laboratory response to repeated cycling. Dry lyophilized cakes are not subject to the ice-interface problem, but they can absorb moisture if a cold vial is opened in humid air before equilibrating, which reintroduces mobility into the cake.

For the approved PDGF-BB topical gel, the labeling instruction is not to freeze — a formulated semi-solid product with its own excipient system. The verified literature contains no freeze–thaw study on purified PDGF, so any specific cycle-count claim would be an extrapolation rather than a reported result.

Degradation and Loss of Activity: What Studies Report

This is where the vocabulary problem becomes most consequential. In the PDGF literature, "degradation" overwhelmingly means regulated proteolysis of receptors and signaling proteins inside living tissue. A 2025 MedComm study reported that a Quaking–cZFP609 axis corrected aberrant vascular smooth muscle cell plasticity by mediating PDGFRβ degradation (PMID 40242156). A 2021 study in Pulmonary Circulation reported that ubiquitin-specific protease 7 mediated PDGF-induced proliferation of pulmonary arterial smooth muscle cells (PMID 34552711), and a 2024 paper in the Journal of Biomedical Science reported that Tudor-SN exacerbated pathological vascular remodeling by promoting polyubiquitination of PTEN via NEDD4-1 (PMID 39237902). Engineered degradation tools extend the same language further: researchers described aptamer-LYTACs for targeted degradation of extracellular and membrane proteins (PMID 36722696) and nanomotor-driven targeting chimeras as accelerators for degradation of extracellular proteins (PMID 39268797). None of these papers describe container-level breakdown, and none should be read as shelf-life evidence.

Physical indicators discussed in general formulation science

The observations below are generic to lyophilized proteins and are not PDGF-specific results from any cited paper:

• Cake appearance: collapse, shrinkage, browning or a melted-looking cake are treated as signs that the dried product experienced moisture or thermal stress.
• Solution clarity: haze, visible particles or fibrils after reconstitution are interpreted as aggregation.
• Volume or seal integrity: loss of vacuum, a compromised stopper, or evidence of moisture ingress indicate the dried state was not maintained.
• Silence is not safety: a normal-looking cake and a clear solution do not establish potency; growth factor activity is defined by assay, not appearance.

How potency was actually assessed in studies

Because appearance is uninformative, the PDGF literature judged activity functionally — through cell proliferation and receptor-dependent signaling readouts, as in the study that reported PDGF-induced pulmonary arterial smooth muscle cell proliferation (PMID 34552711) — or through tissue-level outcomes in animal models, as in the fibrin matrix wound-healing work (PMID 36093431) and the PDGF-BB hydrogel skin study (PMID 35473604). Those are laboratory endpoints, not checks available outside a research setting.

Limits of the evidence on this page

Three limits are worth restating. First, the compound-specific PDGF papers gathered here are biology and bioengineering studies, not stability studies, so they describe what PDGF did in cells, matrices and animals rather than how a preparation behaved over time in storage. Second, the one lyophilization paper cited (PMID 32006480) concerns a serum-derived eyedrop, so it supports only the general point that drying is used to stabilise growth-factor-containing biologics. Third, general formulation principles are patterns across many proteins; they explain why cold and dry conditions are conventional, but they do not supply numbers for PDGF.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making decisions about any substance discussed here. Readers looking for background on what PDGF is and what the receptor biology literature covers can consult PeptideU's PDGF overview, and the general storage guide covers the cross-compound formulation science referenced above. Nothing here is a handling instruction, a protocol, or a statement about human use.

References

• Lyophilized Autologous Serum Eyedrops: Experimental and Comparative Study (American Journal of Ophthalmology, 2020)
• PDGF-BB-derived supramolecular hydrogel for promoting skin wound healing (Journal of Nanobiotechnology, 2022)
• Therapeutic arteriogenesis by factor-decorated fibrin matrices promotes wound healing in diabetic mice (Journal of Tissue Engineering, 2022)
• Biologically inspired bioactive hydrogels for scarless corneal repair (Science Advances, 2024)
• Diet-regulated production of PDGFcc by macrophages controls energy storage (Science, 2021)
• Circuit Design Features of a Stable Two-Cell System (Cell, 2018)
• Quaking-cZFP609 Axis Remedies Aberrant Plasticity of Vascular Smooth Muscle Cells via Mediating Platelet-Derived Growth Factor Receptor β Degradation (MedComm, 2025)
• Ubiquitin-specific protease 7 mediates platelet-derived growth factor-induced pulmonary arterial smooth muscle cells proliferation (Pulmonary Circulation, 2021)
• Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1 (Journal of Biomedical Science, 2024)
• Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins (Angewandte Chemie International Edition, 2023)
• Nanomotor-Driven Targeting Chimeras as Accelerators for the Degradation of Extracellular Proteins (Small, 2024)